US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Dermata Therapeutics, Inc. - Common Stock
(NQ:
DRMA
)
0.8600
-0.0500 (-5.49%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dermata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Stocks to Watch: WETO, PRSO, DRMA, SNES Highlight Robotics, Defense, Skincare and Revenue Growth
October 15, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Graphene Manufacturing (OTCQX: GMGMF) Reports Battery Energy Density Gains
October 15, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
October 15, 2026
- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments - - Over 71% of study participants were graded as having overall...
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
August 25, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
August 21, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
August 17, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
August 11, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
August 05, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
May 13, 2026
Via
ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
April 02, 2026
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
March 26, 2026
Via
ACCESS Newswire
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
March 10, 2026
Via
ACCESS Newswire
Dermata Opens a New Chapter with the Release of Tome Skincare
March 05, 2026
Via
ACCESS Newswire
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
January 20, 2026
Via
ACCESS Newswire
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 29, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 24, 2025
Via
ACCESS Newswire
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
December 04, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 14, 2025
Via
ACCESS Newswire
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
October 02, 2025
Via
ACCESS Newswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
September 17, 2025
Via
ACCESS Newswire
Life Science Virtual Investor Forum Agenda Announced for September 18th
September 16, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
September 16, 2025
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
September 10, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Via
ACCESS Newswire
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 08, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Via
ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Via
ACCESS Newswire
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
Via
ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
Next >
